SlideShare a Scribd company logo
1 of 4
Download to read offline
Effect of Flux Decay
on Virus Retention
#05
#01
#02
#03
#04
Application
Report
Virus
Clearance
Introduction
This application note describes virus retention
properties of Virosart® CPV, the Sartorius
20 nm Polyethersulfone membrane virus
filter. This application note outlines virus
retention data for Virosart® CPV with
increasing flux decay profiles for several
different proteins.
Background
20 nm retentive virus removal filters are
a well established, robust method for
clearing both large and small viruses within
a purifi­cation process. In order to validate
the efficiency of these filters, a virus spiking
trial must be performed. It has been shown
that the virus reduction capability of some
virus removal filters decreases with increasing
flux decay (1). This decrease in log reduction
value (LRV) is dependent on several factors
including protein concentration, product
purity and plugging mechanism (adsorptive
vs. pore plugging). The influence of these
parameters on the overall flow decay profile
of each virus filter has to be examined case
by case.
Material & Methods
– Different protein types and concentrations
have been used to determine LRV versus
flux decay profiles for Virosart® CPV
– Spiking studies were performed with Viro-
sart® CPV Minisarts using bacteriophage
PP7, a small 25 nm non enveloped ss-RNA
Pseudomonas phage (Leviviridae family)
at different spiking concentrations.
– PP7 is the model virus widely used by filter
manufacturers for the evaluation of reten-
tion characteristics of 20 nm virus filters
– Sartorius has shown the feasibility of PP7
as a model virus for mammalian viruses (2)
– Instantaneous samples were taken at vari-
ous levels of flow decay and virus retention
was determined.
– For each test, protein type, protein concen-
tration, pH, buffer type and composition
as well as the spiking concentration are
outlined
– Graphs show LRV over Flow decay profile
0,0
1,0
2,0
3,0
4,0
5,0
6,0
7,0
0 10 20 30 40 50 60 70 80 90 100
Flow Decay (%)
LRV
LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z1 #1
LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z1 #2
LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z1 #3
LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z2 #1
LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z2 #2
LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z2 #3
LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z3 #1
LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z3 #2
LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z3 #3
Results
Graph 1: LRV versus Flow decay – Monoclonal Antibody	
9 mg/ml MAb in 20 mM Tris, 25 mM NaCl, pH 7.2, Virosart® CPV Minisart
Lot number 0650773/R50/Z1; Upstream titer 3.0 + 107/ml
0,00,00,00,0
1,01,01,01,0
2,02,02,02,0
3,03,03,03,0
4,04,04,04,0
5,05,05,05,0
6,06,06,06,0
7,07,07,07,0
0000 10101010 20202020 30303030 40404040 50505050 60606060 70707070 80808080 90909090 100100100100
Flow Decay (%)Flow Decay (%)Flow Decay (%)Flow Decay (%)
LRVLRVLRVLRV
LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z1 #1
LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z1 #2
LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z1 #3
LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z3 #1
LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z3 #2
LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z3 #3
LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z4 #1
LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z4 #2
LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z4 #3
Graph 2: LRV versus Flow decay – Human Derived IVIG
IVIG 1.2% in 0.2 M glycine buffer, pH 7.1, Virosart® CPV Minisart
Lot number 0650773/R50 Z1-4, 2 bar, Upstream titer 2.2 + 107/ml
Summary
The 20 nm Virosart® CPV membrane filter
provides reliable virus retention of small
viruses.
The capability of Virosart® CPV to retain more
than 4 log of small non enveloped viruses is
not necessarily correlated to the flux decay.
Reliable retention of more than 4 log has
been shown for flux decay profiles of up to
90%.
The data shown are typical examples for
different protein types, buffers and concen-
trations. They can not, however, be used to
predict the performance in general.
It is up to the end user to determine what
level of flow decay and virus retention is
acceptable for his process in order to achieve
the desired virus retention.
1
: “Normal Flow Virus Filtration – Detection
and Assessment of Endpoint in Bioprocess-
ing”, Mark Bailey, E. Lilly, May 2005 PDA
Viral Safety Conference
2
: “The Sartorius virus and contaminant
removal platform”, K. Tarrach, Sartorius
Downstream Technology Forum Barcelona,
November 23rd 2004
0,00,00,00,0
1,01,01,01,0
2,02,02,02,0
3,03,03,03,0
4,04,04,04,0
5,05,05,05,0
6,06,06,06,0
7,07,07,07,0
0%0%0%0% 10%10%10%10% 20%20%20%20% 30%30%30%30% 40%40%40%40% 50%50%50%50% 60%60%60%60% 70%70%70%70% 80%80%80%80% 90%90%90%90% 100%100%100%100%
Flow decay (%)Flow decay (%)Flow decay (%)Flow decay (%)
LRVLRVLRVLRV
LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650613/R19/Z5 #1
LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650613/R19/Z5 #2
LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650613/R19/Z5 #3
LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650613/R19/Z3 #1
LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650613/R19/Z3 #2
LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650613/R19/Z3 #3
LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650143/R5/Z1 #1
LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650143/R5/Z1 #2
LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650143/R5/Z1 #3
0,00,00,00,0
1,01,01,01,0
2,02,02,02,0
3,03,03,03,0
4,04,04,04,0
5,05,05,05,0
6,06,06,06,0
7,07,07,07,0
0000 10101010 20202020 30303030 40404040 50505050 60606060 70707070 80808080 90909090
Flow decay (%)Flow decay (%)Flow decay (%)Flow decay (%)
LRVLRVLRVLRV
LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z1 #1
LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z1 #2
LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z1 #3
LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z2 #1
LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z2 #2
LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z2 #3
LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z4 #1
LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z4 #2
LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z4 #3
Graph 3: LRV versus Flow decay – BSA
BSA 0.1%, 20 mM potassium phosphate buffer, Virosart® CPV Minisart
Lot number 0650613/R19/Z5, 0650613/R19/Z3, 2 bar, Upstream titer 6.4 + 107/ml
Graph 4: LRV versus Flow decay – Fab2
5 mg/ml in 25 mM Tris, pH 6.5, 2 bar, Virosart® CPV Minisart Lot number 0650773/R50Z1,2,4
Upstream titer 3.0 + 107/ml
Sales and Service Contacts
For further contacts, visit www.sartorius-stedim.com
Europe
Germany
Sartorius Stedim Biotech GmbH
August-Spindler-Strasse 11
37079 Goettingen
Phone +49.551.308.0
Fax +49.551.308.3289
Sartorius Stedim Systems GmbH
Robert-Bosch-Strasse 5–7
34302 Guxhagen
Phone +49.5665.407.0
Fax +49.5665.407.2200
France
Sartorius Stedim FMT S.A.S.
ZI des Paluds
Avenue de Jouques – CS 91051
13781 Aubagne Cedex
Phone +33.442.845600
Fax +33.442.845619
Sartorius Stedim France SAS
ZI des Paluds
Avenue de Jouques – CS 71058
13781 Aubagne Cedex
Phone +33.442.845600
Fax +33.442.846545
Austria
Sartorius Stedim Austria GmbH
Modecenterstrasse 22
1030 Vienna
Phone +43.1.7965763.18
Fax +43.1.796576344
Belgium
Sartorius Stedim Belgium N.V.
Leuvensesteenweg, 248/B
1800 Vilvoorde
Phone +32.2.756.06.80
Fax +32.2.756.06.81
Hungary
Sartorius Stedim Hungária Kft.
Kagyló u. 5
2092 Budakeszi
Phone +36.23.457.227
Fax +36.23.457.147
Italy
Sartorius Stedim Italy S.p.A.
Via dell’Antella, 76/A
50012 Antella-Bagno a Ripoli (FI)
Phone +39.055.63.40.41
Fax +39.055.63.40.526
Netherlands
Sartorius Stedim Netherlands B.V.
Phone +31.30.60.25.080
Fax +31.30.60.25.099
filtratie.nederland@sartorius-stedim.com
Poland
Sartorius Stedim Poland Sp. z o.o.
ul. Wrzesinska 70
62-025 Kostrzyn
Phone +48.61.647.38.40
Fax +48.61.879.25.04
Russian Federation
LLC “Sartorius ICR”and LLC “Biohit”
Uralskaya str. 4, Lit. B
199155, Saint-Petersburg
Phone +7.812.327.5.327
Fax +7.812.327.5.323
Spain
Sartorius Stedim Spain, S.A.U.
Avda. de la Industria, 32
Edificio PAYMA
28108 Alcobendas (Madrid)
Phone +34.902.110.935
Fax +34.91.358.96.23
Switzerland
Sartorius Stedim Switzerland AG
Ringstrasse 24 a
8317 Tagelswangen
Phone +41.52.354.36.36
Fax +41.52.354.36.46
U.K.
Sartorius Stedim UK Ltd.
Longmead Business Centre
Blenheim Road, Epsom
Surrey KT19 9 QQ
Phone +44.1372.737159
Fax +44.1372.726171
Ukraine
LLC “Biohit”
Post Box 440 “B”
01001 Kiev, Ukraine
Phone +380.44.411.4918
Fax +380.50.623.3162
America
USA
Sartorius Stedim North America Inc.
5 Orville Drive, Suite 200
Bohemia, NY 11716
Toll-Free +1.800.368.7178
Fax +1.631.254.4253
Argentina
Sartorius Argentina S.A.
Int. A. Ávalos 4251
B1605ECS Munro
Buenos Aires
Phone +54.11.4721.0505
Fax +54.11.4762.2333
Brazil
Sartorius do Brasil Ltda
Avenida Senador Vergueiro 2962
São Bernardo do Campo
CEP 09600-000 - SP- Brasil
Phone +55.11.4362.8900
Fax + 55.11.4362.8901
Mexico
Sartorius de México S.A. de C.V.
Circuito Circunvalación Poniente
No. 149
Ciudad Satélite
53100, Estado de México
México
Phone +52.5555.62.1102
Fax +52.5555.62.2942
Asia|Pacific
Australia
Sartorius Stedim Australia Pty. Ltd.
Unit 5, 7-11 Rodeo Drive
Dandenong South Vic 3175
Phone +61.3.8762.1800
Fax +61.3.8762.1828
China
Sartorius Stedim Biotech (Beijing) Co. Ltd.
No. 33 Yu’an Road
Airport Industrial Park Zone B
Shunyi District, Beijing 101300
Phone +86.10.80426516
Fax +86.10.80426580
Sartorius Stedim (Shanghai)
Trading Co. Ltd
3rd Floor, North Wing, Tower 1
No. 4560 Jinke Road
Zhangjiang Hi-Tech Park
Pudong District
Shanghai 201210, China
Phone +86.21.68782300
Fax +86.21.68782332|68782882
Sartorius Stedim Biotech (Beijing) Co. Ltd.
Guangzhou Representative Office
Unit K, Building 23
Huihua Commerce  Trade Building
No. 80 Xianlie Middle Road
Guangzhou 510070
Phone +86.20.37618687|37618651
Fax +86.20.37619051
India
Sartorius Stedim India Pvt. Ltd.
#69/2-69/3, NH 48, Jakkasandra
Nelamangala Tq
562 123 Bangalore, India
Phone +91.80.4350.5250
Fax +91.80.4350.5253
Japan
Sartorius Stedim Japan K.K.
4th Fl., Daiwa Shinagawa North Bldg.
8-11, Kita-Shinagawa 1-chome
Shinagawa-ku, Tokyo, 140-0001 Japan
Phone +81.3.4331.4300
Fax +81.3.4331.4301
Malaysia
Sartorius Stedim Malaysia Sdn. Bhd.
Lot L3-E-3B, Enterprise 4
Technology Park Malaysia
Bukit Jalil
57000 Kuala Lumpur, Malaysia
Phone +60.3.8996.0622
Fax +60.3.8996.0755
Singapore
Sartorius Stedim Singapore Pte. Ltd.
1 Science Park Road,
The Capricorn, #05-08A,
Singapore Science Park II
Singapore 117528
Phone +65.6872.3966
Fax +65.6778.2494
South Korea
Sartorius Korea Biotech Co., Ltd.
8th Floor, Solid Space B/D,
PanGyoYeok-Ro 220, BunDang-Gu
SeongNam-Si, GyeongGi-Do, 463-400
Phone +82.31.622.5700
Fax +82.31.622.5799
www.sartorius-stedim.com
Specificationssubjecttochangewithoutnotice.PrintedintheEUonpaperbleachedwithoutchlorine.W
PublicationNo.:SPK4109-e150304·OrderNo.:85030-531-03·Ver.03|2015

More Related Content

Viewers also liked

Plataforma Tecnológica para Gestión de Diagnósticos
Plataforma Tecnológica para Gestión de DiagnósticosPlataforma Tecnológica para Gestión de Diagnósticos
Plataforma Tecnológica para Gestión de DiagnósticosISOTools Chile
 
Avcılık Sunum
Avcılık SunumAvcılık Sunum
Avcılık Sunumalisimsek
 
Jacopo Antoniazzi, La Spezia 29 ottobre 2015
Jacopo Antoniazzi, La Spezia 29 ottobre 2015Jacopo Antoniazzi, La Spezia 29 ottobre 2015
Jacopo Antoniazzi, La Spezia 29 ottobre 2015infoprogetto
 
Extrusion modelling
Extrusion modellingExtrusion modelling
Extrusion modellingLewisB2013
 
Mining Investment Impact on the Peruvian Development
Mining Investment Impact on the  Peruvian DevelopmentMining Investment Impact on the  Peruvian Development
Mining Investment Impact on the Peruvian Developmenttellyspaucar
 
魏玓:媒體與資本主義
魏玓:媒體與資本主義魏玓:媒體與資本主義
魏玓:媒體與資本主義人社 募哲
 
Cartera Estimada de Proyectos Mineros
Cartera Estimada de Proyectos MinerosCartera Estimada de Proyectos Mineros
Cartera Estimada de Proyectos Minerostellyspaucar
 
Presentation2 iico
Presentation2 iicoPresentation2 iico
Presentation2 iicoFlenny Wong
 
Drawing project 1 july 2015_integration (1)
Drawing project 1 july 2015_integration (1)Drawing project 1 july 2015_integration (1)
Drawing project 1 july 2015_integration (1)Flenny Wong
 
DevOps, Agile, Scrum, ITIL, & ITSM: Excerpts From ITx 2016
DevOps, Agile, Scrum, ITIL, & ITSM: Excerpts From ITx 2016DevOps, Agile, Scrum, ITIL, & ITSM: Excerpts From ITx 2016
DevOps, Agile, Scrum, ITIL, & ITSM: Excerpts From ITx 2016Ritchie Grijaldo
 
Prostate Cancer Presentationv2
Prostate Cancer Presentationv2Prostate Cancer Presentationv2
Prostate Cancer Presentationv2Sanjay Yeleswaram
 

Viewers also liked (16)

Plataforma Tecnológica para Gestión de Diagnósticos
Plataforma Tecnológica para Gestión de DiagnósticosPlataforma Tecnológica para Gestión de Diagnósticos
Plataforma Tecnológica para Gestión de Diagnósticos
 
Img 9195
Img 9195Img 9195
Img 9195
 
Avcılık Sunum
Avcılık SunumAvcılık Sunum
Avcılık Sunum
 
Jacopo Antoniazzi, La Spezia 29 ottobre 2015
Jacopo Antoniazzi, La Spezia 29 ottobre 2015Jacopo Antoniazzi, La Spezia 29 ottobre 2015
Jacopo Antoniazzi, La Spezia 29 ottobre 2015
 
Extrusion modelling
Extrusion modellingExtrusion modelling
Extrusion modelling
 
Mining Investment Impact on the Peruvian Development
Mining Investment Impact on the  Peruvian DevelopmentMining Investment Impact on the  Peruvian Development
Mining Investment Impact on the Peruvian Development
 
Grace ThomsonCV
Grace ThomsonCVGrace ThomsonCV
Grace ThomsonCV
 
Boletim01 segundona
Boletim01 segundonaBoletim01 segundona
Boletim01 segundona
 
魏玓:媒體與資本主義
魏玓:媒體與資本主義魏玓:媒體與資本主義
魏玓:媒體與資本主義
 
Mahdie Ghanbari
Mahdie GhanbariMahdie Ghanbari
Mahdie Ghanbari
 
Cartera Estimada de Proyectos Mineros
Cartera Estimada de Proyectos MinerosCartera Estimada de Proyectos Mineros
Cartera Estimada de Proyectos Mineros
 
DP & John Donne
DP & John DonneDP & John Donne
DP & John Donne
 
Presentation2 iico
Presentation2 iicoPresentation2 iico
Presentation2 iico
 
Drawing project 1 july 2015_integration (1)
Drawing project 1 july 2015_integration (1)Drawing project 1 july 2015_integration (1)
Drawing project 1 july 2015_integration (1)
 
DevOps, Agile, Scrum, ITIL, & ITSM: Excerpts From ITx 2016
DevOps, Agile, Scrum, ITIL, & ITSM: Excerpts From ITx 2016DevOps, Agile, Scrum, ITIL, & ITSM: Excerpts From ITx 2016
DevOps, Agile, Scrum, ITIL, & ITSM: Excerpts From ITx 2016
 
Prostate Cancer Presentationv2
Prostate Cancer Presentationv2Prostate Cancer Presentationv2
Prostate Cancer Presentationv2
 

Similar to Appl_Virosart-01_SPK4109-e

Continuous On-Line Microbial Monitoring of Pharmaceutical Waters
Continuous On-Line Microbial Monitoring of Pharmaceutical WatersContinuous On-Line Microbial Monitoring of Pharmaceutical Waters
Continuous On-Line Microbial Monitoring of Pharmaceutical WatersAlliance Technical Sales, Inc.
 
PVR P1-60 mcg.doc
PVR P1-60 mcg.docPVR P1-60 mcg.doc
PVR P1-60 mcg.doc9160676107
 
MicroPRO, A Rapid Microbiology Method Based on Flow Cytometry
MicroPRO, A Rapid Microbiology Method Based on Flow CytometryMicroPRO, A Rapid Microbiology Method Based on Flow Cytometry
MicroPRO, A Rapid Microbiology Method Based on Flow Cytometryguest32bcc5
 
Sucrose low in nanoparticulate impurities for biopharmaceutical formulations
Sucrose low in nanoparticulate impurities for biopharmaceutical formulationsSucrose low in nanoparticulate impurities for biopharmaceutical formulations
Sucrose low in nanoparticulate impurities for biopharmaceutical formulationsMilliporeSigma
 
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On ExperienceParvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On ExperienceMilliporeSigma
 
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On ExperienceParvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On ExperienceMerck Life Sciences
 
Render MA120 microbiology AST/ID system.pptx
Render MA120 microbiology AST/ID system.pptxRender MA120 microbiology AST/ID system.pptx
Render MA120 microbiology AST/ID system.pptxRobinZhang30
 
New Ultra-High Capacity TOYOPEARL® Protein A Resin
New Ultra-High Capacity TOYOPEARL® Protein A Resin New Ultra-High Capacity TOYOPEARL® Protein A Resin
New Ultra-High Capacity TOYOPEARL® Protein A Resin Tosoh Bioscience GmbH
 
Barrick SETAC Brussels.pdf
Barrick SETAC Brussels.pdfBarrick SETAC Brussels.pdf
Barrick SETAC Brussels.pdfAndrew Barrick
 
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...PerkinElmer, Inc.
 
BILS 2015 Tosoh Bioscience
BILS 2015 Tosoh BioscienceBILS 2015 Tosoh Bioscience
BILS 2015 Tosoh BioscienceGBX Events
 
Bacterial detection of platelets
Bacterial detection of plateletsBacterial detection of platelets
Bacterial detection of plateletsRafiq Ahmad
 
Hematology technology
Hematology technologyHematology technology
Hematology technologymanueldsx
 
Process development guidance for AAV and lentivirus manufacturing based on co...
Process development guidance for AAV and lentivirus manufacturing based on co...Process development guidance for AAV and lentivirus manufacturing based on co...
Process development guidance for AAV and lentivirus manufacturing based on co...Merck Life Sciences
 
The Potency Determination of 15 Cannabinoids using the Hemp Analyzer
The Potency Determination of 15 Cannabinoids using the Hemp Analyzer The Potency Determination of 15 Cannabinoids using the Hemp Analyzer
The Potency Determination of 15 Cannabinoids using the Hemp Analyzer Shimadzu Scientific Instruments
 
A Novel approach for quantitative real-time particle analysis of lentiviral v...
A Novel approach for quantitative real-time particle analysis of lentiviral v...A Novel approach for quantitative real-time particle analysis of lentiviral v...
A Novel approach for quantitative real-time particle analysis of lentiviral v...Myriade
 
Monitoring Released N-Glycans in Biopharma Development/QC with Fluorescence &...
Monitoring Released N-Glycans in Biopharma Development/QC with Fluorescence &...Monitoring Released N-Glycans in Biopharma Development/QC with Fluorescence &...
Monitoring Released N-Glycans in Biopharma Development/QC with Fluorescence &...Waters Corporation
 

Similar to Appl_Virosart-01_SPK4109-e (20)

Continuous On-Line Microbial Monitoring of Pharmaceutical Waters
Continuous On-Line Microbial Monitoring of Pharmaceutical WatersContinuous On-Line Microbial Monitoring of Pharmaceutical Waters
Continuous On-Line Microbial Monitoring of Pharmaceutical Waters
 
PVR P1-60 mcg.doc
PVR P1-60 mcg.docPVR P1-60 mcg.doc
PVR P1-60 mcg.doc
 
MicroPRO, A Rapid Microbiology Method Based on Flow Cytometry
MicroPRO, A Rapid Microbiology Method Based on Flow CytometryMicroPRO, A Rapid Microbiology Method Based on Flow Cytometry
MicroPRO, A Rapid Microbiology Method Based on Flow Cytometry
 
Sucrose low in nanoparticulate impurities for biopharmaceutical formulations
Sucrose low in nanoparticulate impurities for biopharmaceutical formulationsSucrose low in nanoparticulate impurities for biopharmaceutical formulations
Sucrose low in nanoparticulate impurities for biopharmaceutical formulations
 
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On ExperienceParvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
 
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On ExperienceParvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
 
Bhargav all reports
Bhargav all reportsBhargav all reports
Bhargav all reports
 
Render MA120 microbiology AST/ID system.pptx
Render MA120 microbiology AST/ID system.pptxRender MA120 microbiology AST/ID system.pptx
Render MA120 microbiology AST/ID system.pptx
 
New Ultra-High Capacity TOYOPEARL® Protein A Resin
New Ultra-High Capacity TOYOPEARL® Protein A Resin New Ultra-High Capacity TOYOPEARL® Protein A Resin
New Ultra-High Capacity TOYOPEARL® Protein A Resin
 
Barrick SETAC Brussels.pdf
Barrick SETAC Brussels.pdfBarrick SETAC Brussels.pdf
Barrick SETAC Brussels.pdf
 
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
 
Cassava breeding and screening activities in China
Cassava breeding and screening activities in ChinaCassava breeding and screening activities in China
Cassava breeding and screening activities in China
 
BILS 2015 Tosoh Bioscience
BILS 2015 Tosoh BioscienceBILS 2015 Tosoh Bioscience
BILS 2015 Tosoh Bioscience
 
Bacterial detection of platelets
Bacterial detection of plateletsBacterial detection of platelets
Bacterial detection of platelets
 
SNAP 2 Brochure
SNAP 2 BrochureSNAP 2 Brochure
SNAP 2 Brochure
 
Hematology technology
Hematology technologyHematology technology
Hematology technology
 
Process development guidance for AAV and lentivirus manufacturing based on co...
Process development guidance for AAV and lentivirus manufacturing based on co...Process development guidance for AAV and lentivirus manufacturing based on co...
Process development guidance for AAV and lentivirus manufacturing based on co...
 
The Potency Determination of 15 Cannabinoids using the Hemp Analyzer
The Potency Determination of 15 Cannabinoids using the Hemp Analyzer The Potency Determination of 15 Cannabinoids using the Hemp Analyzer
The Potency Determination of 15 Cannabinoids using the Hemp Analyzer
 
A Novel approach for quantitative real-time particle analysis of lentiviral v...
A Novel approach for quantitative real-time particle analysis of lentiviral v...A Novel approach for quantitative real-time particle analysis of lentiviral v...
A Novel approach for quantitative real-time particle analysis of lentiviral v...
 
Monitoring Released N-Glycans in Biopharma Development/QC with Fluorescence &...
Monitoring Released N-Glycans in Biopharma Development/QC with Fluorescence &...Monitoring Released N-Glycans in Biopharma Development/QC with Fluorescence &...
Monitoring Released N-Glycans in Biopharma Development/QC with Fluorescence &...
 

Appl_Virosart-01_SPK4109-e

  • 1. Effect of Flux Decay on Virus Retention #05 #01 #02 #03 #04 Application Report Virus Clearance
  • 2. Introduction This application note describes virus retention properties of Virosart® CPV, the Sartorius 20 nm Polyethersulfone membrane virus filter. This application note outlines virus retention data for Virosart® CPV with increasing flux decay profiles for several different proteins. Background 20 nm retentive virus removal filters are a well established, robust method for clearing both large and small viruses within a purifi­cation process. In order to validate the efficiency of these filters, a virus spiking trial must be performed. It has been shown that the virus reduction capability of some virus removal filters decreases with increasing flux decay (1). This decrease in log reduction value (LRV) is dependent on several factors including protein concentration, product purity and plugging mechanism (adsorptive vs. pore plugging). The influence of these parameters on the overall flow decay profile of each virus filter has to be examined case by case. Material & Methods – Different protein types and concentrations have been used to determine LRV versus flux decay profiles for Virosart® CPV – Spiking studies were performed with Viro- sart® CPV Minisarts using bacteriophage PP7, a small 25 nm non enveloped ss-RNA Pseudomonas phage (Leviviridae family) at different spiking concentrations. – PP7 is the model virus widely used by filter manufacturers for the evaluation of reten- tion characteristics of 20 nm virus filters – Sartorius has shown the feasibility of PP7 as a model virus for mammalian viruses (2) – Instantaneous samples were taken at vari- ous levels of flow decay and virus retention was determined. – For each test, protein type, protein concen- tration, pH, buffer type and composition as well as the spiking concentration are outlined – Graphs show LRV over Flow decay profile 0,0 1,0 2,0 3,0 4,0 5,0 6,0 7,0 0 10 20 30 40 50 60 70 80 90 100 Flow Decay (%) LRV LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z1 #1 LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z1 #2 LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z1 #3 LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z2 #1 LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z2 #2 LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z2 #3 LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z3 #1 LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z3 #2 LRV CPV MAb 8mg/ml, 0.1µm prefiltered, 0650773/R50/Z3 #3 Results Graph 1: LRV versus Flow decay – Monoclonal Antibody 9 mg/ml MAb in 20 mM Tris, 25 mM NaCl, pH 7.2, Virosart® CPV Minisart Lot number 0650773/R50/Z1; Upstream titer 3.0 + 107/ml 0,00,00,00,0 1,01,01,01,0 2,02,02,02,0 3,03,03,03,0 4,04,04,04,0 5,05,05,05,0 6,06,06,06,0 7,07,07,07,0 0000 10101010 20202020 30303030 40404040 50505050 60606060 70707070 80808080 90909090 100100100100 Flow Decay (%)Flow Decay (%)Flow Decay (%)Flow Decay (%) LRVLRVLRVLRV LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z1 #1 LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z1 #2 LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z1 #3 LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z3 #1 LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z3 #2 LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z3 #3 LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z4 #1 LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z4 #2 LRV CPV IVIG 2mg/ml, 0.1µm prefiltered, 0650773/R50/Z4 #3 Graph 2: LRV versus Flow decay – Human Derived IVIG IVIG 1.2% in 0.2 M glycine buffer, pH 7.1, Virosart® CPV Minisart Lot number 0650773/R50 Z1-4, 2 bar, Upstream titer 2.2 + 107/ml
  • 3. Summary The 20 nm Virosart® CPV membrane filter provides reliable virus retention of small viruses. The capability of Virosart® CPV to retain more than 4 log of small non enveloped viruses is not necessarily correlated to the flux decay. Reliable retention of more than 4 log has been shown for flux decay profiles of up to 90%. The data shown are typical examples for different protein types, buffers and concen- trations. They can not, however, be used to predict the performance in general. It is up to the end user to determine what level of flow decay and virus retention is acceptable for his process in order to achieve the desired virus retention. 1 : “Normal Flow Virus Filtration – Detection and Assessment of Endpoint in Bioprocess- ing”, Mark Bailey, E. Lilly, May 2005 PDA Viral Safety Conference 2 : “The Sartorius virus and contaminant removal platform”, K. Tarrach, Sartorius Downstream Technology Forum Barcelona, November 23rd 2004 0,00,00,00,0 1,01,01,01,0 2,02,02,02,0 3,03,03,03,0 4,04,04,04,0 5,05,05,05,0 6,06,06,06,0 7,07,07,07,0 0%0%0%0% 10%10%10%10% 20%20%20%20% 30%30%30%30% 40%40%40%40% 50%50%50%50% 60%60%60%60% 70%70%70%70% 80%80%80%80% 90%90%90%90% 100%100%100%100% Flow decay (%)Flow decay (%)Flow decay (%)Flow decay (%) LRVLRVLRVLRV LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650613/R19/Z5 #1 LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650613/R19/Z5 #2 LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650613/R19/Z5 #3 LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650613/R19/Z3 #1 LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650613/R19/Z3 #2 LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650613/R19/Z3 #3 LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650143/R5/Z1 #1 LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650143/R5/Z1 #2 LRV CPV BSA 1mg/ml, 0.1µm prefiltered, 0650143/R5/Z1 #3 0,00,00,00,0 1,01,01,01,0 2,02,02,02,0 3,03,03,03,0 4,04,04,04,0 5,05,05,05,0 6,06,06,06,0 7,07,07,07,0 0000 10101010 20202020 30303030 40404040 50505050 60606060 70707070 80808080 90909090 Flow decay (%)Flow decay (%)Flow decay (%)Flow decay (%) LRVLRVLRVLRV LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z1 #1 LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z1 #2 LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z1 #3 LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z2 #1 LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z2 #2 LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z2 #3 LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z4 #1 LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z4 #2 LRV CPV Fab(2) 5mg/ml, 0.2µm prefiltered, 0650773/R50/Z4 #3 Graph 3: LRV versus Flow decay – BSA BSA 0.1%, 20 mM potassium phosphate buffer, Virosart® CPV Minisart Lot number 0650613/R19/Z5, 0650613/R19/Z3, 2 bar, Upstream titer 6.4 + 107/ml Graph 4: LRV versus Flow decay – Fab2 5 mg/ml in 25 mM Tris, pH 6.5, 2 bar, Virosart® CPV Minisart Lot number 0650773/R50Z1,2,4 Upstream titer 3.0 + 107/ml
  • 4. Sales and Service Contacts For further contacts, visit www.sartorius-stedim.com Europe Germany Sartorius Stedim Biotech GmbH August-Spindler-Strasse 11 37079 Goettingen Phone +49.551.308.0 Fax +49.551.308.3289 Sartorius Stedim Systems GmbH Robert-Bosch-Strasse 5–7 34302 Guxhagen Phone +49.5665.407.0 Fax +49.5665.407.2200 France Sartorius Stedim FMT S.A.S. ZI des Paluds Avenue de Jouques – CS 91051 13781 Aubagne Cedex Phone +33.442.845600 Fax +33.442.845619 Sartorius Stedim France SAS ZI des Paluds Avenue de Jouques – CS 71058 13781 Aubagne Cedex Phone +33.442.845600 Fax +33.442.846545 Austria Sartorius Stedim Austria GmbH Modecenterstrasse 22 1030 Vienna Phone +43.1.7965763.18 Fax +43.1.796576344 Belgium Sartorius Stedim Belgium N.V. Leuvensesteenweg, 248/B 1800 Vilvoorde Phone +32.2.756.06.80 Fax +32.2.756.06.81 Hungary Sartorius Stedim Hungária Kft. Kagyló u. 5 2092 Budakeszi Phone +36.23.457.227 Fax +36.23.457.147 Italy Sartorius Stedim Italy S.p.A. Via dell’Antella, 76/A 50012 Antella-Bagno a Ripoli (FI) Phone +39.055.63.40.41 Fax +39.055.63.40.526 Netherlands Sartorius Stedim Netherlands B.V. Phone +31.30.60.25.080 Fax +31.30.60.25.099 filtratie.nederland@sartorius-stedim.com Poland Sartorius Stedim Poland Sp. z o.o. ul. Wrzesinska 70 62-025 Kostrzyn Phone +48.61.647.38.40 Fax +48.61.879.25.04 Russian Federation LLC “Sartorius ICR”and LLC “Biohit” Uralskaya str. 4, Lit. B 199155, Saint-Petersburg Phone +7.812.327.5.327 Fax +7.812.327.5.323 Spain Sartorius Stedim Spain, S.A.U. Avda. de la Industria, 32 Edificio PAYMA 28108 Alcobendas (Madrid) Phone +34.902.110.935 Fax +34.91.358.96.23 Switzerland Sartorius Stedim Switzerland AG Ringstrasse 24 a 8317 Tagelswangen Phone +41.52.354.36.36 Fax +41.52.354.36.46 U.K. Sartorius Stedim UK Ltd. Longmead Business Centre Blenheim Road, Epsom Surrey KT19 9 QQ Phone +44.1372.737159 Fax +44.1372.726171 Ukraine LLC “Biohit” Post Box 440 “B” 01001 Kiev, Ukraine Phone +380.44.411.4918 Fax +380.50.623.3162 America USA Sartorius Stedim North America Inc. 5 Orville Drive, Suite 200 Bohemia, NY 11716 Toll-Free +1.800.368.7178 Fax +1.631.254.4253 Argentina Sartorius Argentina S.A. Int. A. Ávalos 4251 B1605ECS Munro Buenos Aires Phone +54.11.4721.0505 Fax +54.11.4762.2333 Brazil Sartorius do Brasil Ltda Avenida Senador Vergueiro 2962 São Bernardo do Campo CEP 09600-000 - SP- Brasil Phone +55.11.4362.8900 Fax + 55.11.4362.8901 Mexico Sartorius de México S.A. de C.V. Circuito Circunvalación Poniente No. 149 Ciudad Satélite 53100, Estado de México México Phone +52.5555.62.1102 Fax +52.5555.62.2942 Asia|Pacific Australia Sartorius Stedim Australia Pty. Ltd. Unit 5, 7-11 Rodeo Drive Dandenong South Vic 3175 Phone +61.3.8762.1800 Fax +61.3.8762.1828 China Sartorius Stedim Biotech (Beijing) Co. Ltd. No. 33 Yu’an Road Airport Industrial Park Zone B Shunyi District, Beijing 101300 Phone +86.10.80426516 Fax +86.10.80426580 Sartorius Stedim (Shanghai) Trading Co. Ltd 3rd Floor, North Wing, Tower 1 No. 4560 Jinke Road Zhangjiang Hi-Tech Park Pudong District Shanghai 201210, China Phone +86.21.68782300 Fax +86.21.68782332|68782882 Sartorius Stedim Biotech (Beijing) Co. Ltd. Guangzhou Representative Office Unit K, Building 23 Huihua Commerce Trade Building No. 80 Xianlie Middle Road Guangzhou 510070 Phone +86.20.37618687|37618651 Fax +86.20.37619051 India Sartorius Stedim India Pvt. Ltd. #69/2-69/3, NH 48, Jakkasandra Nelamangala Tq 562 123 Bangalore, India Phone +91.80.4350.5250 Fax +91.80.4350.5253 Japan Sartorius Stedim Japan K.K. 4th Fl., Daiwa Shinagawa North Bldg. 8-11, Kita-Shinagawa 1-chome Shinagawa-ku, Tokyo, 140-0001 Japan Phone +81.3.4331.4300 Fax +81.3.4331.4301 Malaysia Sartorius Stedim Malaysia Sdn. Bhd. Lot L3-E-3B, Enterprise 4 Technology Park Malaysia Bukit Jalil 57000 Kuala Lumpur, Malaysia Phone +60.3.8996.0622 Fax +60.3.8996.0755 Singapore Sartorius Stedim Singapore Pte. Ltd. 1 Science Park Road, The Capricorn, #05-08A, Singapore Science Park II Singapore 117528 Phone +65.6872.3966 Fax +65.6778.2494 South Korea Sartorius Korea Biotech Co., Ltd. 8th Floor, Solid Space B/D, PanGyoYeok-Ro 220, BunDang-Gu SeongNam-Si, GyeongGi-Do, 463-400 Phone +82.31.622.5700 Fax +82.31.622.5799 www.sartorius-stedim.com Specificationssubjecttochangewithoutnotice.PrintedintheEUonpaperbleachedwithoutchlorine.W PublicationNo.:SPK4109-e150304·OrderNo.:85030-531-03·Ver.03|2015